Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. 1989

J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
University of Southern California School of Medicine, Los Angeles.

The Childrens Cancer Study Group conducted four therapeutic studies on a total of 1006 children with acute nonlymphocytic leukemia from 1972 to 1983. This report describes the therapeutic strategies of these studies and examines trends in induction rates and long-term outcome over this period. The remission induction rate has changed from 58% in 1972 to 1975 to 80% for the period 1980 to 1983, and the induction mortality dropped from 20% to 6%. Four-year survival probabilities from time of diagnosis have almost doubled from 19% to 36%. Few deaths occurred more than 5 years after diagnosis: children surviving in first remission beyond 5 years had a 92% survival rate and an 86% relapse-free survival rate over the next 5 years. In contrast, median survival after a marrow relapse was less than 6 months and the 6-year survival probability was 4%. The leukocyte count was a significant prognostic factor, and although the mortality for infants was high initially, long-term survival was not decreased.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
July 1989, Cancer research,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
January 1981, Medical and pediatric oncology,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
January 1990, Haematology and blood transfusion,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
October 1984, Cancer treatment reports,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
August 1988, Pediatric clinics of North America,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
January 1992, Medical and pediatric oncology,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
May 1991, Cancer,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
September 1981, Blood,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
January 1983, Medical and pediatric oncology,
J D Buckley, and R L Chard, and R L Baehner, and M E Nesbit, and B C Lampkin, and W G Woods, and G D Hammond
August 1993, Cancer,
Copied contents to your clipboard!